For example, in the United Stated, adjuvant atezolizumab is approved after adjuvant platinum-based chemotherapy for all patients whose resected stage II-IIIA tumors express PD-L1 on ≥1% of tumor cells, while oncologists in the European Union are authorized to administer adjuvant atezolizumab after chemotherapy only in patients whose resected stage II-IIIA tumors express PD-L1 on ≥50% of tumor cells stage (with the exclusion of patients whose tumors harbour EGFR mutations and ALK rearrangements), and always after chemotherapy. Here, ALK is linked to neoplasm.